CYP17 POLYMORPHISMS AND PROSTATE CANCER OUTCOMES

被引：0
|
作者：
Wright, Jonathan L.
Lin, Daniel W.
Kwon, Erika M.
Kolb, Suzanne
Feng, Ziding
Koopmeiners, Joseph
Ostrander, Elaine A.
Stanford, Janet L.
机构：
来源：
JOURNAL OF UROLOGY | 2009年 / 181卷 / 04期
关键词：
D O I：
10.1016/S0022-5347(09)62164-9
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
2142
引用
收藏
页码：777 / 777
页数：1
相关论文
共 50 条
  • [21] CYP17 lyase inhibitors as therapeutic agents for the treatment of prostate cancer
    Huang, Audris
    Balog, Aaron
    Jayaraman, Lata
    Frennesson, David
    Saulnier, Mark
    Velaparthi, Upender
    Liu, Pei-Ying
    Darne, Chetan
    Vite, Gregory
    Trainor, George
    Gottardis, Marco
    Spires, Thomas
    Rodriguez, Vanessa
    Rizzo, Cheryl
    Obermeier, Mary
    Elzinga, Paul
    Todderud, Gordon
    Fan, Yi
    Newitt, John
    Beyer, Sophie
    Vyas, Dinesh
    Fura, Aberra
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [22] CYP17 gene promoter allelic variant is not associated with prostate cancer
    Lin, CC
    Wu, HC
    Chen, WC
    Chen, HY
    Tsai, FJ
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (04) : 262 - 265
  • [23] CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population
    Souiden, Yousra
    Mandouani, Manel
    Chaieb, Kamel
    Elkamel, Rafik
    Mandouani, Kacem
    CANCER EPIDEMIOLOGY, 2011, 35 (05) : 480 - 484
  • [24] CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
    Alex, Anitha B.
    Pal, Sumanta K.
    Agarwal, Neeraj
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (04) : 267 - 275
  • [25] Replacement of Imidazolyl by Pyridyl in Biphenylmethylenes Results in Selective CYP17 and Dual CYP17/CYP11B1 Inhibitors for the Treatment of Prostate Cancer
    Hu, Qingzhong
    Jagusch, Carsten
    Hille, Ulrike E.
    Haupenthal, Joerg
    Hartmann, Rolf W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (15) : 5749 - 5758
  • [26] Cyp17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia:: A population-based study in China
    Madigan, MP
    Gao, YT
    Deng, J
    Pfeiffer, RM
    Chang, BL
    Zheng, SQ
    Meyers, DA
    Stanczyk, FZ
    Xu, JF
    Hsing, AW
    INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (02) : 271 - 275
  • [27] Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany
    Vesovic, Z
    Herkommer, K
    Vogel, W
    Paiss, T
    Maier, C
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1303 - 1307
  • [28] CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity
    Berstein, LM
    Imyanitov, EN
    Kovalevskij, AJ
    Maximov, SJ
    Vasilyev, DA
    Buslov, KG
    Sokolenko, AP
    Iyevleva, AG
    Chekmariova, EV
    Thijssen, JHH
    CANCER LETTERS, 2004, 207 (02) : 191 - 196
  • [29] CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans
    Kittles, RA
    Panguluri, RK
    Chen, WD
    Massac, A
    Ahaghotu, C
    Jackson, A
    Ukoli, F
    Adams-Campbell, L
    Isaacs, W
    Dunston, GM
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (09) : 943 - 947
  • [30] The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer
    Haiman, CA
    Stampfer, MJ
    Giovannucci, E
    Ma, J
    Decalo, NE
    Kantoff, PW
    Hunter, DJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (07) : 743 - 748
12345